- Home
- APOG vs AMLX Comparison
APOG vs AMLX Comparison
Compare APOG & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APOG
- AMLX
- Stock Information
- Founded
- APOG 1949
- AMLX 2014
- Country
- APOG United States
- AMLX United States
- Employees
- APOG N/A
- AMLX N/A
- Industry
- APOG Auto Parts:O.E.M.
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- APOG Consumer Discretionary
- AMLX Health Care
- Exchange
- APOG Nasdaq
- AMLX Nasdaq
- Market Cap
- APOG 817.4M
- AMLX 749.9M
- IPO Year
- APOG N/A
- AMLX 2022
- Fundamental
- Price
- APOG $37.94
- AMLX $14.90
- Analyst Decision
- APOG Hold
- AMLX Strong Buy
- Analyst Count
- APOG 1
- AMLX 7
- Target Price
- APOG $45.00
- AMLX $16.86
- AVG Volume (30 Days)
- APOG 268.7K
- AMLX 1.9M
- Earning Date
- APOG 10-09-2025
- AMLX 11-06-2025
- Dividend Yield
- APOG 2.74%
- AMLX N/A
- EPS Growth
- APOG N/A
- AMLX N/A
- EPS
- APOG 2.05
- AMLX N/A
- Revenue
- APOG $1,391,854,000.00
- AMLX N/A
- Revenue This Year
- APOG $6.91
- AMLX N/A
- Revenue Next Year
- APOG $0.41
- AMLX N/A
- P/E Ratio
- APOG $18.51
- AMLX N/A
- Revenue Growth
- APOG 1.19
- AMLX N/A
- 52 Week Low
- APOG $37.25
- AMLX $2.60
- 52 Week High
- APOG $87.93
- AMLX $15.94
- Technical
- Relative Strength Index (RSI)
- APOG 29.35
- AMLX 62.33
- Support Level
- APOG $42.84
- AMLX $13.60
- Resistance Level
- APOG $38.99
- AMLX $15.15
- Average True Range (ATR)
- APOG 1.57
- AMLX 1.05
- MACD
- APOG -0.69
- AMLX -0.03
- Stochastic Oscillator
- APOG 3.20
- AMLX 71.09
About APOG Apogee Enterprises Inc.
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company generates revenue geographically from the United States, Canada, and Brazil, with the majority coming from the United States.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.